Bevatas 300mg Injection (Bevacizumab): The Definitive B2B Procurement Guide for Global Wholesalers and Pharmacies

The global oncology therapeutics market demands highly effective, bio-engineered solutions to combat advanced malignancies. Bevatas 300mg Injection, manufactured by Intas Pharmaceuticals Ltd., stands as an industry-leading biosimilar to Bevacizumab. It has transformed targeted cancer treatment protocols across the globe.

For international healthcare buyers, hospital procurement departments, and pharmacy chains in major global trade hubs—including New York (USA), Bristol (UK), Sydney (Australia), and Riyadh (Saudi Arabia)—sourcing this vital life-saving drug requires a trusted, highly compliant logistics partner.

PRIMECARE IMPEX, a premier division of the GROUP OF PRIME CARE IMPEX PVT. LTD., is a leading pharmaceutical exporter from India, bulk supplier, and distributor. We specialize in the temperature-controlled export of high-value oncology medications.

Technical Specifications & Product Overview

Strategic Mechanism of Action (MOA)

Bevatas 300mg functions through localized targeted therapy rather than broad cellular destruction.

Inhibition of Angiogenesis

The active substance, Bevacizumab, is a recombinant humanized monoclonal antibody designed to selectively bind to Vascular Endothelial Growth Factor (VEGF). VEGF is a signaling protein secreted by tumor cells to stimulate the growth of new blood vessels (angiogenesis) to supply the tumor with oxygen and essential nutrients.

Tumor Starvation and Regression

By binding directly to VEGF, Bevatas prevents the protein from interacting with its receptors (Flt-1 and KDR) on the surface of endothelial cells. This action breaks down the tumor's existing vascular architecture, inhibits the formation of new blood vessels, and restricts tumor growth and metastasis. This effectively starves the malignancy while enhancing the delivery of co-administered chemotherapeutic agents.

Approved Clinical Indications

Bevatas 300mg Injection is widely indicated, often in combination with fluoropyrimidine-based chemotherapy, for the treatment of advanced and metastatic cancers:

• Metastatic Colorectal Cancer (mCRC): First- or second-line treatment for patients with metastatic carcinoma of the colon or rectum.

• Non-Small Cell Lung Cancer (NSCLC): First-line treatment of unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC.

• Metastatic Breast Cancer (mBC): Used in combination with taxanes for patients with advanced or recurrent breast cancer.

• Glioblastoma / Advanced Brain Tumors: Used as a monotherapy for patients with progressive glioblastoma following prior therapy.

• Advanced/Metastatic Renal Cell Carcinoma (Kidney Cancer): Combined with interferon alfa for treating metastatic kidney malignancies.

• Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Approved for advanced stages to extend progression-free survival.

• Cervical Cancer: Indicated for persistent, recurrent, or metastatic carcinoma of the cervix.

• 
  

Standard Storage and Cold-Chain Maintenance

Because Bevatas 300mg is a biological protein molecule, strict adherence to cold-chain storage parameters is mandatory to preserve biological efficacy and prevent protein denaturation:

Storage Temperature: Store exclusively in a refrigerator between 2°C and 8°C (36°F to 46°F).

Handling Protections:

• Do not freeze. Freezing permanently destroys the molecular structure of the monoclonal antibody.

• Do not shake. Vigorous agitation can cause protein aggregation.

• Keep the vial inside its original outer carton to protect the solution from direct light exposure.

Regulatory Documentation & Quality Assurance

As an established bulk supplier, PRIMECARE IMPEX provides comprehensive regulatory documentation with every shipment to facilitate smooth customs clearance in the USA, UK, Australia, and the Middle East:

• Certificate of Analysis (COA): Verifying batch-specific purity, concentration, and sterility.

• Commercial Invoice & Packing List: Detailing exact batch numbers and expiry information.

• Certificate of Origin (COO): Issued by competent Indian authorities.

• Material Safety Data Sheet (MSDS): Outlining professional handling protocols.

• Temperature Logs: Comprehensive cold-chain data sheets compiled from advanced data loggers embedded in transport containers.

Main Clinical Advantages of Bevatas 300mg

1. Proven Bioequivalence: Delivers therapeutic efficacy, safety profiles, and immunogenicity comparable to the reference innovator biologic.

2. Cost-Effective Procurement: Offers a highly affordable biosimilar price point, reducing financial overhead for oncology clinics and healthcare budgets.

3. Synergistic Capabilities: Successfully pairs with multiple standard chemotherapy regimens to maximize survival outcomes.

Safety Profile & Side Effects

While Bevatas 300mg is highly targeted, systemic inhibition of VEGF can influence normal vascular structures, leading to notable side effects that require monitoring by an oncologist:

Common Side Effects

• Hypertension (Elevated blood pressure)

• Epistaxis (Nosebleeds) and minor mucosal bleeding

• Headaches, fatigue, and generalized weakness

• Proteinuria (Excess protein in the urine)

• Altered or impaired sense of taste and dry skin

• Mild gastrointestinal distress (constipation, diarrhea, nausea)

• Serious Adverse Reactions (Requiring Immediate Intervention

• Gastrointestinal Perforations: Development of abnormal holes in the stomach or intestinal walls.

• Impaired Wound Healing: Increased risk of wound complications; treatment must be suspended prior to and following major surgeries.

• Severe Hemorrhage: Severe internal bleeding or pulmonary hemorrhage.

• Thromboembolic Events: Increased risk of arterial blood clots, stroke, or myocardial infarction.